Clin Mol Hepatol.  2016 Sep;22(3):309-318. 10.3350/cmh.2016.0042.

Liver transplantation for advanced hepatocellular carcinoma

• Lee HW
• Suh KS

• KMID: 2373130
• DOI: http://doi.org/10.3350/cmh.2016.0042

Abstract

There has been ongoing debate that the Milan criteria may be too strict that a significant number of patients who could benefit from liver transplantation (LT) might have been excluded. Based on this idea, various studies have been conducted to further expand the Milan criteria and give more HCC patients a chance of cure. In deceased donor LT (DDLT) setting, expansion of the criteria is relatively tempered because the results of LT for HCC should be comparable to those of patients with non-malignant indications. On the other hand, in living donor LT (LDLT) situation, liver grafts are not public resources. The acceptable target outcomes for LDLT might be much lower than those for DDLT. Patients with biologically favorable tumors might have excellent survivals after LT despite morphological advanced HCCs. Therefore, the significance and utility of biological tumor parameters for selecting suitable LT candidates have been increased to predict HCC recurrence after LT. Although there is no consensus regarding the use of prognostic biomarkers in LT selection criteria for HCC, the combination of conventional morphological parameters and new promising biomarkers could help us refine and expand the LT criteria for HCC in the near future.

Keyword

Carcinoma; Hepatocellular; Transplantation, Liver; Selection Criteria; Expanded criteria; Biomarker

MeSH Terms

Biomarkers, Tumor/analysis
Carcinoma, Hepatocellular/diagnostic imaging/pathology/*therapy
Humans
Liver Neoplasms/diagnostic imaging/pathology/*therapy
Liver Transplantation
Neoplasm Recurrence, Local
Neoplasm Staging
Patient Selection
Positron-Emission Tomography
Biomarkers, Tumor